Canadian Court Invalidates Idenix Patent for Sovaldi Compound

摘要

A Canadian court has invalidated a patent held by Idenix Pharmaceuticals Inc., upholding an application by Gilead Sciences Inc. to protect itself from infringement claims for its patented hepatitis drug Sovaldi (Gilead Sciences Inc. v. Idenix Pharmaceuticals Inc., Fed. Ct., No. T-1156-12, 11/2/15). Idenix's patent is invalid on the basis of lack of utility and insufficiency, and there is no basis for Idenix's counterclaim of invalidity against Gilead's patent for sofosbu-vir, the active ingredient in Sovaldi, the Federal Court of Canada said on Nov. 2.